Kamada Ltd, Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Law to Decentralize Personalized Drug Manufacturing in UK

A legislation to decentralize personalized drug manufacturing in UK...

UK government, Manufacturing, Investment, Clinical trials

The UK government will improve manufacturing and commercialisation as...

How to Take Creatine Safely: Water Intake, Dosing, and Special Considerations

Creatine is one of the most trusted and researched...

The Israeli health authorities have signed a supply agreement for the investigational Covid-19 plasma-derived Immunoglobulin (IgG), to be supplied by Kamada Ltd., a biopharmaceutical company which is partnered with Kedrion Biopharma in the development of the new anti-Covid-19 therapy.

The Israeli company will manufacture the product, to be supplied to the Ministry of Health, from convalescent plasma collected by the Israeli National Blood Services, a division of Magen David Adom (MADA), and additional Israeli medical institutions. The initial order to be supplied in the next few months is sufficient to treat approximately 500 hospitalized patients.

“We are pleased to work in collaboration with Kamada on the development and global distribution of this important therapy, which we hope will help patients in Israel and around the world,” said Paolo Marcucci, chairman of Kedrion Biopharma.

In April 2020 Kedrion and Kamada established a global collaboration for the development, manufacturing, and distribution of a plasma-derived IgG product as a potential treatment for Covid-19.

The companies’ U.S. clinical development of a plasma-derived IgG product as a potential Covid-19 treatment is expected to begin in early 2021 pending IND acceptance by the FDA.

Val Romberg, Kedrion’s CEO, said the news from Israel was “a welcome milestone” and added, “The progress made in Israel is a positive and encouraging sign for patients everywhere.”

Kedrion, in collaboration with Kamada, is continuing with the development of new anti-Covid therapies together with its research partner Columbia University Irving Medical Center in New York. In July, Kedrion announced it was forming a research partnership with Columbia University Medical Center that is aimed at helping to develop a new plasma-based anti-Covid therapy.

Latest stories

Related stories

Law to Decentralize Personalized Drug Manufacturing in UK

A legislation to decentralize personalized drug manufacturing in UK...

UK government, Manufacturing, Investment, Clinical trials

The UK government will improve manufacturing and commercialisation as...

How to Take Creatine Safely: Water Intake, Dosing, and Special Considerations

Creatine is one of the most trusted and researched...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back